1-4 of 4
Joseph P Boni, PhD
Close
Sort by
Journal Articles

Comparison of 2 Doses of Intravenous (IV) Temsirolimus (Temsr) in Patients with Relapsed/Refractory Mantle Cell Lymphoma (MCL)

Wojciech Jurczak, MD, Sundra Ramanathan, MBBS FRCPA FRACP, Pratyush Giri, MBBS, FRACP, FRCPA, Francesco Di Raimondo, MD, Heidi Mocikova, MD, PhD, Jill Clancy, Mariajose Lechuga, MD, Michelle Casey, PhD, Joseph P Boni, PhD, Agnieszka Giza, MD, Georg Hess, MD
Journal: Blood
Blood (2016) 128 (22): 1775.
https://doi.org/10.1182/blood.V128.22.1775.1775
Published: 2016
Journal Articles

Exploring Relationships of Exposure, Pharmacodynamic Changes and Gene Expression to Clinical Outcome in Adults with Acute Lymphoblastic Leukemia Receiving Inotuzumab Ozogamicin

Luke Fostvedt, A. Douglas Laird, Jean-Claude Marshall, Sherry Li, Joseph P. Boni, PhD BS
Journal: Blood
Blood (2015) 126 (23): 3698.
https://doi.org/10.1182/blood.V126.23.3698.3698
Published: 2015
Journal Articles

Weekly Inotuzumab Ozogamicin (InO) In Adult Patients With Relapsed Or Refractory CD22-Positive Acute Lymphoblastic Leukemia (ALL)

Daniel J. DeAngelo, MD, Ph.D, Wendy Stock, M.D., Andrei R. Shustov, MD, Michaela Liedtke, MD, Charles A. Schiffer, MD, Revathi Ananthakrishnan, Joseph P. Boni, PhD, Kenneth Luu, Katherine Liau, Erik Vandendries, MD, Anjali S. Advani, MD
Journal: Blood
Blood (2013) 122 (21): 3906.
https://doi.org/10.1182/blood.V122.21.3906.3906
Published: 2013
Journal Articles

Phase I Study Of Inotuzumab Ozogamicin (InO) Combined With R-GDP For Relapsed/Refractory CD22+ B-Cell Non-Hodgkin Lymphoma (B-NHL)

Randeep Sangha, Andrew Davies, PhD, Nam H. Dang, MD, PhD, Michinori Ogura, MD, PhD, David A. MacDonald, MD, Angela Volkert, Revathi Ananthakrishnan, Kenneth Luu, Joseph P. Boni, PhD, Erik Vandendries, MD, Yeow-Tee YT Goh, MD
Journal: Blood
Blood (2013) 122 (21): 1821.
https://doi.org/10.1182/blood.V122.21.1821.1821
Published: 2013